论文部分内容阅读
美国临床肿瘤学会第25届年会上,西弗吉尼亚大学泌尿科主任D、L、Lamm博士报告了西南肿瘤研究组(SWOG),46一单位大规模Ⅲ期临床研究的结果,他提出在防止或延缓非浸润性膀胱癌复发方面,膀胱内卡介苗(BCG)免疫治疗优于膀胱内单一药物(如何霉素等)治疗。BCG治疗膀胱原位癌与用阿霉素相比,复发率减少1.5倍,肿瘤控制期延长8倍。免疫治疗的效果明显优于化疗。
At the 25th annual meeting of the American Society of Clinical Oncology, Dr. D, L, and Lamm, Director of Urology at West Virginia University, reported the results of a large-scale Phase III clinical study of the 46-unit Southwestern Cancer Research Group (SWOG), he proposed To delay the recurrence of non-invasive bladder cancer, intravesical BCG (BCG) immunotherapy is superior to single intravesical therapy (such as cystatin). BCG treatment of bladder cancer in situ compared with doxorubicin, the recurrence rate decreased 1.5 times, tumor control period extended 8 times. The effect of immunotherapy is significantly better than chemotherapy.